These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 29451296)

  • 1. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
    Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
    Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls.
    Kim WT; Yun SJ; Yan C; Jeong P; Kim YH; Lee IS; Kang HW; Park S; Moon SK; Choi YH; Choi YD; Kim IY; Kim J; Kim WJ
    Yonsei Med J; 2016 Jul; 57(4):865-71. PubMed ID: 27189278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
    Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
    Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
    Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
    Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.
    Zhou BF; Wei JH; Chen ZH; Dong P; Lai YR; Fang Y; Jiang HM; Lu J; Zhou FJ; Xie D; Luo JH; Chen W
    Oncotarget; 2016 Jul; 7(27):41703-41714. PubMed ID: 27203388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
    Peng J; Chen YT; Chen CL; Li L
    Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
    Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
    BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers.
    Shen C; Sun Z; Chen D; Su X; Jiang J; Li G; Lin B; Yan J
    OMICS; 2015 Jan; 19(1):1-11. PubMed ID: 25562196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bladder cancer biomarker discovery using global metabolomic profiling of urine.
    Wittmann BM; Stirdivant SM; Mitchell MW; Wulff JE; McDunn JE; Li Z; Dennis-Barrie A; Neri BP; Milburn MV; Lotan Y; Wolfert RL
    PLoS One; 2014; 9(12):e115870. PubMed ID: 25541698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine.
    Yang C; Sun X; Wang H; Lu T; Wu K; Guan Y; Tang J; Liang J; Sun R; Guo Z; Zheng S; Wu X; Jiang H; Jiang X; Zhong B; Niu X; Sun S; Wang X; Chen M; Fu G
    Int J Mol Med; 2019 Nov; 44(5):1952-1962. PubMed ID: 31545404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease.
    Tripathi P; Somashekar BS; Ponnusamy M; Gursky A; Dailey S; Kunju P; Lee CT; Chinnaiyan AM; Rajendiran TM; Ramamoorthy A
    J Proteome Res; 2013 Jul; 12(7):3519-28. PubMed ID: 23731241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raman chemometric urinalysis (Rametrix) as a screen for bladder cancer.
    Huttanus HM; Vu T; Guruli G; Tracey A; Carswell W; Said N; Du P; Parkinson BG; Orlando G; Robertson JL; Senger RS
    PLoS One; 2020; 15(8):e0237070. PubMed ID: 32822394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
    Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
    Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival.
    von Rundstedt FC; Rajapakshe K; Ma J; Arnold JM; Gohlke J; Putluri V; Krishnapuram R; Piyarathna DB; Lotan Y; Gödde D; Roth S; Störkel S; Levitt JM; Michailidis G; Sreekumar A; Lerner SP; Coarfa C; Putluri N
    J Urol; 2016 Jun; 195(6):1911-9. PubMed ID: 26802582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary mRNA biomarker panel for the detection of urothelial carcinoma.
    Urquidi V; Netherton M; Gomes-Giacoia E; Serie D; Eckel-Passow J; Rosser CJ; Goodison S
    Oncotarget; 2016 Jun; 7(25):38731-38740. PubMed ID: 27231851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary metabolomic signature of muscle-invasive bladder cancer: A multiplatform approach.
    Jacyna J; Wawrzyniak R; Balayssac S; Gilard V; Malet-Martino M; Sawicka A; Kordalewska M; Nowicki Ł; Kurek E; Bulska E; Patejko M; Markuszewski M; Gutknecht P; Matuszewski M; Siebert J; Kaliszan R; Markuszewski MJ
    Talanta; 2019 Sep; 202():572-579. PubMed ID: 31171223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-analyte assay for the non-invasive detection of bladder cancer.
    Goodison S; Chang M; Dai Y; Urquidi V; Rosser CJ
    PLoS One; 2012; 7(10):e47469. PubMed ID: 23094052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer.
    Juracek J; Peltanova B; Dolezel J; Fedorko M; Pacik D; Radova L; Vesela P; Svoboda M; Slaby O; Stanik M
    J Cell Mol Med; 2018 Mar; 22(3):2033-2038. PubMed ID: 29363887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer.
    Sahu D; Lotan Y; Wittmann B; Neri B; Hansel DE
    Cancer Med; 2017 Sep; 6(9):2106-2120. PubMed ID: 28766915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
    Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
    Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.